Meloxicam in Mohs Micrographic Surgery

Part of paid clinical trials in Oklahoma City, Oklahoma.

Sponsor
University of Oklahoma
Study ID
NCT07200544
Phase
PHASE4
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 110 Years
Healthy Volunteers
Not accepted

Interventions

  • Meloxicam 7.5 mg — DRUG
    This intervention is the mandatory oral Meloxicam 7.5mg dose after Mohs closure.
  • Meloxicam 15 mg — DRUG
    This intervention is the mandatory oral Meloxicam 15mg dose after Mohs closure.
  • Acetaminophen 500mg — DRUG
    This randomized control group will take a mandatory one-time dose of 500 mg acetaminophen with alternating 200 mg ibuprofen and 500 mg acetaminophen (standard of care) every 3 hours for pain.

Study Details

The goal of this clinical trial is to explore alternative methods of postoperative pain control in Mohs micrographic surgery. The main aims are: * To provide more information to the Mohs surgery community regarding postoperative pain control. * Reducing pain improves the overall comfort and well-being of patients, leading to a better post-operative experience. * To provide patients with an alternative and potentially superior NSAID for pain control (compared to standard-of-care ibuprofen). Researchers will compare 1) a single of dose Meloxicam 7.5 mg, followed by acetaminophen 500 mg; 2) a single dose of Meloxicam 15 mg, followed by acetaminophen 500 mg; 3) a single dose of acetaminophen 500 mg, followed by alternating ibuprofen 200 mg and acetaminophen 500 mg to see which better moderate pain control and patient satisfaction. Participants will be asked to complete pain and patient satisfaction surveys.

Key Dates

Start date
Oct 15, 2025
Status verified
Dec 2025
Primary completion
Jun 2, 2026
Completion
Aug 2, 2026

Study Design

Enrollment
300 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION

Arms

  • Active Comparator: Standard of Care (Acetaminophen/Ibuprofen)
    This randomized control group will take a mandatory one-time dose of 500 mg acetaminophen with alternating 200 mg ibuprofen and 500 mg acetaminophen (standard of care) every 3 hours for pain.
  • Experimental: Meloxicam 7.5 mg
    This randomly assigned experimental group will take a mandatory one-time dose of oral Meloxicam 7.5 mg with as-needed acetaminophen 500 mg every 3 hours. Administration of Meloxicam will be upon completion of Mohs closure.
  • Experimental: Meloxicam 15 mg
    This randomly assigned experimental group will take a mandatory one-time dose of oral Meloxicam 15 mg with as-needed acetaminophen 500 mg every 3 hours. Administration of Meloxicam will be upon completion of Mohs closure.

Primary Outcome Measure

To evaluate the effect of the use of Meloxicam vs SoC on post-operative pain levels in participants undergoing Mohs micrographic surgery. [ Time Frame: From enrollment to suture removal, wound check or flap takedown (7-21 days) ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of Oklahoma Health Sciences CenterOklahoma CityOklahoma73104
Chase Pitchford
[email protected]
405-271-6110
Lindsey Collins
[email protected]
405-271-6110
Lindsey Collins, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Oklahoma City, OK

By condition
Skin cancer
By specialty
OncologySkin cancerDermatology
By research site
University of Oklahoma Health Sciences Center· Oklahoma City, OK

Related Studies